Roche collaborates with Sentara Consolidated Laboratories for diagnostic solutions


Pharmaceutical and diagnostic firm Roche has entered a strategic alliance with Sentara Consolidated Laboratories, recognising the organisation as a Roche Molecular Centre of Excellence (MCOE).

In 2002, Roche started its MCOE network by partnering and capitalising on information in molecular testing to enable non-competing regional laboratories in the US to assist in enhancing new test methods and technology.

Sentara Consolidated Laboratories will provide new molecular and tissue diagnostic technologies to physicians and patients.

The lab will also help Roche to develop next-generation diagnostic solutions.

Roche Diagnostics president and chief executive officer Jack Phillips said: "Roche is very pleased to welcome Sentara Consolidated Laboratories into the MCOE network.

"The network will especially benefit from their expertise in lab quality, automation and informatics, and we look forward to working together to implement molecular technologies for the advancement of personalised medicine."

"The network will especially benefit from their expertise in lab quality, automation and informatics, and we look forward to working together to implement molecular technologies for the advancement of personalised medicine."

Sentara Healthcare operates 12 hospitals and several patient care centres across Virginia and North Carolina, and employs 28,000 people.

Sentara Consolidated Laboratory Services acting director Tabetha Sundin said: "This relationship with the MCOE network will help keep Sentara on the forefront of diagnostics.

"It will also support our focus on improving efficiency within the lab and ensuring that the right tests and technology are used at the right time."

In addition to Sentara, the MCOE designation has been awarded to 32 diagnostic laboratories through strategic collaboration to optimise the use of molecular solutions in laboratory testing.